Surf Bio, a Palo Alto, CA-based biopharmaceutical firm commercializing a novel drug stabilization platform, has obtained a $1.6M grant from the Invoice & Melinda Gates Basis.
The corporate intends to make use of the quantity to judge using its lead know-how towards growing the thermostability and deliverability of a monoclonal antibody in low- and middle-income international locations.
Led by CEO Bryan Mazlish, Surf Bio is a preclinical biopharmaceutical firm that’s leveraging a novel biotechnology platform to develop enhanced therapeutic options for oncology, autoimmune ailments, infectious ailments, gene remedy, and different therapeutic areas. It supplies novel polymer know-how that allows the formulation of biologics at greater concentrations and in a extra thermostable kind than is at present obtainable.
Commenting on the information, Bryan Mazlish mentioned: “We’re thrilled to obtain help from the Invoice & Melinda Gates Basis to advance using our know-how to allow higher entry to biologics in low- and middle-income international locations.”
FinSMEs
30/04/2024
